Rhythm Pharmaceuticals, Inc. - Special Call Transcript
Good day, ladies and gentlemen, and welcome to the Rhythm Pharmaceuticals Conference Call. (Operator Instructions) Please be advised that the call is being recorded at the company's request.
At this time, I would like to turn the call over to David Connolly, Head of Investor Relations and Corporate Communications at Rhythm. Please proceed.
Thank you, and thank you to everyone for joining us today to review the top line results from our 2 pivotal Phase III studies of setmelanotide for the treatment of POMC deficiency obesity and LEPR deficiency obesity. Please note the press release issued earlier today and the presentation we're using for this conference call are available on the Investors & Media section of the Rhythm website.
On today's call are Dr. Keith Gottesdiener, Chief Executive Officer, Rhythm; and Dr. Murray Stewart, Chief Medical Officer, who will provide an overview of these data and what they mean for patients with rare genetic disorders
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |